ANNUAL REPORT2017

Contents

Treatment Advances & Awareness ............................................ 1

Professional Development ......................................................... 2

Organizational Health ............................................................... 3

AASLD Membership Growth ..................................................... 3

FY2017 Combined Financial Position ........................................ 4

FY2017 Combined Net Assets .................................................. 4

FY2017 Combined Revenue & Expenses ................................... 5

FY2017 Combined Revenue ..................................................... 5

FY2017 Combined Expenses ..................................................... 6

AASLD 2017 Governing Board .................................................. 6

AASLD Foundation 2017 Board of Trustees ............................... 7

In Remembrance ...................................................................... 7

VisionTo Prevent and Cure Liver Disease

AASLD MissionTo advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care.

AASLD Foundation MissionTo invest in innovative hepatology research and in the people who study and treat liver disease.

A A S L D 2 0 1 7 A N N U A L R E P O R T 1

Treatment Advances & Awareness

Clinical Practice Guidelines

Global Outreach & Engagement

Guidelines for the Treatment of Chronic Hepatitis (Includes 3 Systematic Reviews)

Released January 2017

Offered International Travel Awards

Exhibited at APASL, EASL and AMH Annual Meetings

Jointly provided global programs with AMH, APASL, ALEH, EASL and SASLT

Provided Sponsorship for the following programs: Gordon Research Conference;

Network of Minority Health Research Investigators 15th Anniversary Annual Meeting;

International HBV Meeting; 24th Annual International HCV Conference; Hepatobiliary

Cancers: Pathobiology and Translational Advances; World Hepatitis Summit

Endorsed programs of: TASL; FDA/CPATH; Chinese Society of Hepatology;

INASL; Hellenic Association for the Study of the Liver

Provided Joint Symposium with EASL and Global Forum at The Liver Meeting® 2017

A M E R I C A N A S S O C I AT I O N F O R T H E S T U D Y O F L I V E R D I S E A S E S2

Professional Development

9,500 +Registrants

2,268Accepted Abstracts

3,643+Postgraduate

Course

2,967+Basic Science Symposium

Attendance

AASLD Webinars

Eight New Webinars in 2017

618Registrants

Emerging Trends Conference

Emerging Trends in NAFLD

384Participants

Clinical Hepatology

Update

174Participants

67Participants

STC: Acute on Chronic Liver Failure

Is it Ready for Clinical Practice?

?

A A S L D 2 0 1 7 A N N U A L R E P O R T 3

AASLD Membership Growth

3597 3683

4129

47314978

0

1000

2000

3000

4000

5000

6000

2017*201620152014201320122011

*This reflects a change in the membership year to July 1 – June 30

3597 3683

4129

4731

4978

0

1000

2000

3000

4000

5000 Corporate Affiliate

Emeritus

Associate

International Trainee*

Trainee

International Fellow

Fellow

International

Regular

20152014201320122011

Actual Years:2011: As of 10/22/112012: As of 1/3/132013: As of 1/3/142014: As of 1/5/152015: As of 12/14/15

*Discontinued 2013

Corporate Affiliate

Emeritus

Associate

International Trainee*

Trainee

International Fellow

Fellow

International

Regular

5313

4733

Organizational Health

AASLD Membership Growth

32%Amount AASLD Membership has

grown since 2012

61New AASLD Fellows

(562 Total)

Ensuring the Future of Hepatology

29New Emerging Liver

Scholars (166 since 2012) MOC Committee

Number of Matches in the New Mentorship Program

240

A M E R I C A N A S S O C I AT I O N F O R T H E S T U D Y O F L I V E R D I S E A S E S4

FY2017 Combined Financial Position

0

10

20

30

40

50

60

Foundation

AASLD

Net Assets $49MLiabilities $11MAssets $60M

$16

Mill

ion

s

$44

$3

$8

$13

$36

FY2017 Combined Net Assets

Permanently Restricted $4,061,850

Temporarily Restricted $4,942,921

Unrestricted Board Designated $7,231,413

Unrestricted Undesignated $32,731,794

67%15%

10%

8%

A A S L D 2 0 1 7 A N N U A L R E P O R T 5

FY2017 Combined Revenue

FY2017 Combined Revenue & Expenses

Revenue $17,627,832

Income from Investments $4,951,657

Expenses -$18,535,802

Surplus $4,043,687

Annual Meeting ($8.4M)

Research Grants & Contributions ($3.6M)

Publications, AASLD Journals & eNews ($2.8M)

Membership Dues & Mailing List Income ($1.5M)

Meetings & Education ($1.1M)

Professional Relations ($117K)

Rental Income ($90K)

48%

20%

16%

9%

6%

1% 0%

For full financial statements refer to aasld.org

A M E R I C A N A S S O C I AT I O N F O R T H E S T U D Y O F L I V E R D I S E A S E S6

FY2017 Combined Expenses

AASLD 2017 Governing Board

PresidentAnna SF Lok, MD, FAASLDUniversity of MichiganAnn Arbor, MI

President-ElectRonald J. Sokol, MD, FAASLDUniversity of Colorado Hospital School of MedicineAurora, CO

SecretaryKimberly Ann Brown, MD, FAASLD Henry Ford Health SystemDetroit, MI

TreasurerBruce A. Luxon, MD, PhD, FAASLDGeorgetown University HospitalWashington, DC

Past-PresidentKeith D. Lindor, MD, FAASLDArizona State UniversityPhoenix, AZ

CouncilorsJorge A. Bezerra, MD, FAASLDCincinnati Children’s Hospital Medical CenterCincinnati, OH

Raymond T. Chung, MD, FAASLDMassachusetts General HospitalBoston, MA

Michael W. Fried, MD, FAASLDUniversity of North CarolinaChapel Hill, NC

Councilors- At-LargeMark J. Czaja, MD, FAASLDEmory University School of MedicineAtlanta, GA

Julie Heimbach, MD, FAASLDMayo Clinic RochesterRochester, MN

Lopa Mishra, MD, FAASLDGeorge Washington UniversityWashington, DC

CEO (Ex-Officio)Steven Echard, IOM, CAEAlexandria, VA

Fundamentals of Liver Disease ($131K)

Marketing & Communications ($714K)

Fundraising ($253K)

Leadership, IT, F&A ($2.6M)

Clinical & Public Policies ($392K)

Professional Relations & Public Awareness ($1.2M)

Meetings & Education ($2.4M)

Membership and Mentorship ($942K)

Publications, AASLD Journals & eNews ($2.2M)

Research & Fellowship Awards ($3.8M)

Annual Meeting ($3.9M)

20%

1%

13%

12%

14%

2%

4%1%

5%

21%

7%

AASLD & AASLD Foundation spends 85% on Programs service functions and 15% on leadership, administration and fundraising.

A A S L D 2 0 1 7 A N N U A L R E P O R T 7

In RemembranceJohn A. Balint, MD

Bennett L. Blitzer, MD

Lawrence Lumeng, MD

John F. Mullane, MD, PhD

Ralph M. Myerson, MD

Irvin H. Strub, MD

Thomas E. Starzl, MD, PhD, FAASLD

Juan Rodés, MD

Lina Popper

AASLD Foundation 2017 Board of Trustees

ChairBruce R. Bacon, MD, FAASLDSaint Louis UniversitySt. Louis, MO

Vice ChairRonald J. Sokol, MD, FAASLDUniversity of ColoradoAurora, CO

TreasurerBruce A. Luxon, MD, PhD, FAASLDGeorgetown UniversityWashington, DC

TrusteesMeena B. Bansal, MDMount Sinai School of MedicineNew York, NY

Jorge A. Bezerra, MD, FAASLDUniversity of CincinnatiCincinnati, OH

Steven L. Flamm, MDNorthwestern University Health SystemChicago, IL

Michael W Fried, MD, FAASLDUniversity of North Carolina at Chapel HillChapel Hill, NC

Arun J. Sanyal, MD, FAASLDVirginia Commonwealth University Richmond, VA

AASLD is the professional home

for the innovators, educators, and

clinicians in hepatology.

1001 North Fairfax Street, 4th Floor | Alexandria, VA 22314 Phone: 703-299-9766 | Fax: 703-299-9622 | www.aasld.org